These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 24700567)
1. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease. Olson KA; West K; McCarthy PL Pharmacotherapy; 2014 Jun; 34(6):e60-4. PubMed ID: 24700567 [TBL] [Abstract][Full Text] [Related]
2. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Choi CJ; Nghiem P Arch Dermatol; 2001 Sep; 137(9):1202-6. PubMed ID: 11559218 [TBL] [Abstract][Full Text] [Related]
3. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Allen A; Siegfried E; Silverman R; Williams ML; Elias PM; Szabo SK; Korman NJ Arch Dermatol; 2001 Jun; 137(6):747-50. PubMed ID: 11405764 [TBL] [Abstract][Full Text] [Related]
4. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. Sánchez AR; Sheridan PJ; Rogers RS J Periodontol; 2004 Apr; 75(4):613-9. PubMed ID: 15152828 [TBL] [Abstract][Full Text] [Related]
6. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation]. Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983 [TBL] [Abstract][Full Text] [Related]
7. Topical tacrolimus--a novel treatment alternative for cutaneous chronic graft-versus-host disease. Elad S; Or R; Resnick I; Shapira MY Transpl Int; 2003 Sep; 16(9):665-70. PubMed ID: 12768230 [TBL] [Abstract][Full Text] [Related]
8. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Eckardt A; Starke O; Stadler M; Reuter C; Hertenstein B Oral Oncol; 2004 Sep; 40(8):811-4. PubMed ID: 15288836 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. Ohashi Y; Minegishi M; Fujie H; Tsuchiya S; Konno T Bone Marrow Transplant; 1997 Mar; 19(6):625-7. PubMed ID: 9085743 [TBL] [Abstract][Full Text] [Related]
10. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118 [TBL] [Abstract][Full Text] [Related]
12. Oral graft vs. host disease in children--treatment with topical tacrolimus ointment. Albert MH; Becker B; Schuster FR; Klein B; Binder V; Adam K; Nienhoff C; Führer M; Borkhardt A Pediatr Transplant; 2007 May; 11(3):306-11. PubMed ID: 17430488 [TBL] [Abstract][Full Text] [Related]
13. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738 [TBL] [Abstract][Full Text] [Related]
14. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414 [TBL] [Abstract][Full Text] [Related]
15. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Yeager AM; Vogelsang GB; Jones RJ; Farmer ER; Altomonte V; Hess AD; Santos GW Blood; 1992 Jun; 79(11):3031-5. PubMed ID: 1586747 [TBL] [Abstract][Full Text] [Related]
16. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. Prot-Labarthe S; Therrien R; Champagne MA; Duval M; Joubert C Bone Marrow Transplant; 2007 Aug; 40(3):295-6. PubMed ID: 17549052 [No Abstract] [Full Text] [Related]
17. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Przepiorka D; Devine S; Fay J; Uberti J; Wingard J Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154 [TBL] [Abstract][Full Text] [Related]